KR102466418B1 - Glp-1 수용체 작용제 및 이의 용도 - Google Patents
Glp-1 수용체 작용제 및 이의 용도 Download PDFInfo
- Publication number
- KR102466418B1 KR102466418B1 KR1020217032471A KR20217032471A KR102466418B1 KR 102466418 B1 KR102466418 B1 KR 102466418B1 KR 1020217032471 A KR1020217032471 A KR 1020217032471A KR 20217032471 A KR20217032471 A KR 20217032471A KR 102466418 B1 KR102466418 B1 KR 102466418B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- oxy
- pyridin
- carboxylic acid
- benzimidazole
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 254
- 238000000034 method Methods 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims description 91
- -1 phosphorus compound Chemical class 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 25
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 12
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- HYBAKUMPISVZQP-DEOSSOPVSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-DEOSSOPVSA-N 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 208000021017 Weight Gain Diseases 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims description 6
- 230000000291 postprandial effect Effects 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 230000004584 weight gain Effects 0.000 claims description 6
- 235000019786 weight gain Nutrition 0.000 claims description 6
- OQTXBPNADRWVRC-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C=C1)F OQTXBPNADRWVRC-UHFFFAOYSA-N 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 208000001280 Prediabetic State Diseases 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 5
- 201000008980 hyperinsulinism Diseases 0.000 claims description 5
- ARXSFJSWUDNZOO-QHCPKHFHSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F ARXSFJSWUDNZOO-QHCPKHFHSA-N 0.000 claims description 4
- ZAULIVVEBASLNV-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C=C1)F ZAULIVVEBASLNV-UHFFFAOYSA-N 0.000 claims description 4
- MXWZLVOFIPRJMR-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C=C1)F MXWZLVOFIPRJMR-UHFFFAOYSA-N 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 208000007976 Ketosis Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- VBPFAHLTCDPLIP-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C=C1)F VBPFAHLTCDPLIP-UHFFFAOYSA-N 0.000 claims description 3
- LZFWKROSKZLYHR-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)O)C=C1)F LZFWKROSKZLYHR-UHFFFAOYSA-N 0.000 claims description 3
- DGUQZFHWJDDMLD-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C=C1)F DGUQZFHWJDDMLD-UHFFFAOYSA-N 0.000 claims description 3
- ACNCYTDELKNLOL-QFIPXVFZSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C=C1)F ACNCYTDELKNLOL-QFIPXVFZSA-N 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000003790 Foot Ulcer Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 3
- 201000001431 Hyperuricemia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 3
- 208000035180 MODY Diseases 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 230000010014 adipocyte dysfunction Effects 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000018631 connective tissue disease Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 230000008694 endothelial dysfunction Effects 0.000 claims description 3
- 208000004104 gestational diabetes Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 230000004140 ketosis Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 3
- 238000002483 medication Methods 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- FKZZWVWCDFMCKX-CVDCTZTESA-N 2-[[(2S)-4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)C=CC(=C1)F FKZZWVWCDFMCKX-CVDCTZTESA-N 0.000 claims description 2
- GGNJOIUGWVJWGJ-SFHVURJKSA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]-5-fluoropyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=C(C=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C)F)C=C1)F GGNJOIUGWVJWGJ-SFHVURJKSA-N 0.000 claims description 2
- XKYHUPKIMCLAID-IBGZPJMESA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C)C=C1)F XKYHUPKIMCLAID-IBGZPJMESA-N 0.000 claims description 2
- GUBXUCWEROKBFD-IBGZPJMESA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C)C=C1)F GUBXUCWEROKBFD-IBGZPJMESA-N 0.000 claims description 2
- JTLADJZARDLFCQ-NRFANRHFSA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)O)C)C=C1)F JTLADJZARDLFCQ-NRFANRHFSA-N 0.000 claims description 2
- IGXAOFNNKAUXCJ-CVDCTZTESA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)C=C1)F IGXAOFNNKAUXCJ-CVDCTZTESA-N 0.000 claims description 2
- RKYFCKIFKKELMF-RXVVDRJESA-N 2-[[(2S)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C)C=C1)F RKYFCKIFKKELMF-RXVVDRJESA-N 0.000 claims description 2
- YZCFDTHBGFWNIS-FQEVSTJZSA-N 2-[[(2S)-4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C)C=C1)F YZCFDTHBGFWNIS-FQEVSTJZSA-N 0.000 claims description 2
- BPLIDKHPZRJBCQ-FQEVSTJZSA-N 2-[[(2S)-4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C)C=C1)F BPLIDKHPZRJBCQ-FQEVSTJZSA-N 0.000 claims description 2
- CFAVRXZUGJHUQM-RDPSFJRHSA-N 2-[[(2S)-4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)C=C1)F CFAVRXZUGJHUQM-RDPSFJRHSA-N 0.000 claims description 2
- OZKITKMVFYBIAG-UGKGYDQZSA-N 2-[[(2S)-4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C)C=C1)F OZKITKMVFYBIAG-UGKGYDQZSA-N 0.000 claims description 2
- UBOFEEKFCBBZCC-FQEVSTJZSA-N 2-[[(2S)-4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C)F)C=C1 UBOFEEKFCBBZCC-FQEVSTJZSA-N 0.000 claims description 2
- UXDMOGBSPKINQS-NRFANRHFSA-N 2-[[(2S)-4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C)C=C1 UXDMOGBSPKINQS-NRFANRHFSA-N 0.000 claims description 2
- FZNRZOTZQPJANW-OFVILXPXSA-N 2-[[(2S)-4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)C=C1 FZNRZOTZQPJANW-OFVILXPXSA-N 0.000 claims description 2
- AKULQFSHEFUQBF-UHFFFAOYSA-N 2-[[4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C=CC(=C1)F AKULQFSHEFUQBF-UHFFFAOYSA-N 0.000 claims description 2
- GZUZQZQINOFHND-UHFFFAOYSA-N 2-[[4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C=CC(=C1)F GZUZQZQINOFHND-UHFFFAOYSA-N 0.000 claims description 2
- IFXPEJAGKQFBER-UHFFFAOYSA-N 2-[[4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)O)C=CC(=C1)F IFXPEJAGKQFBER-UHFFFAOYSA-N 0.000 claims description 2
- MGOLYDAGSTYTCT-QHCPKHFHSA-N 2-[[4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=CC(=C1)F MGOLYDAGSTYTCT-QHCPKHFHSA-N 0.000 claims description 2
- CMOLDHCZCNUBKV-NRFANRHFSA-N 2-[[4-[6-[(2,4-difluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound FC1=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C=CC(=C1)F CMOLDHCZCNUBKV-NRFANRHFSA-N 0.000 claims description 2
- FIUTUKCXJKLYNY-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C=C1)F FIUTUKCXJKLYNY-UHFFFAOYSA-N 0.000 claims description 2
- LYPNLENSLKGIJB-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-(1,3-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC2=CN=CO2)C=C(C=C3)C(=O)O)C=C1)F LYPNLENSLKGIJB-UHFFFAOYSA-N 0.000 claims description 2
- HEOZZICHEQVNNT-QFIPXVFZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HEOZZICHEQVNNT-QFIPXVFZSA-N 0.000 claims description 2
- OGNAGORTOWDZPV-FQEVSTJZSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C=C1)F OGNAGORTOWDZPV-FQEVSTJZSA-N 0.000 claims description 2
- JHTWEGZYAKIQIS-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,2-oxazol-5-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CC=NO2)C=C(C=C3)C(=O)O)C=C1)F JHTWEGZYAKIQIS-UHFFFAOYSA-N 0.000 claims description 2
- BMPHLUBITKQXBW-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)O)C=C1)F BMPHLUBITKQXBW-UHFFFAOYSA-N 0.000 claims description 2
- WLEWXMLOPOQSFY-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2CC=2OC=CN=2)C=C1)F WLEWXMLOPOQSFY-UHFFFAOYSA-N 0.000 claims description 2
- ZPTQGMVSXQKVJA-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-4-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC=2N=COC=2)C=C(C=C3)C(=O)O)C=C1)F ZPTQGMVSXQKVJA-UHFFFAOYSA-N 0.000 claims description 2
- UZWPHEBZMXBQBX-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C=C1)F UZWPHEBZMXBQBX-UHFFFAOYSA-N 0.000 claims description 2
- ZNJWWBZJDHDSLA-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(1-methoxycyclobutyl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2(CCC2)OC)C=C(C=C3)C(=O)O)C=C1)F ZNJWWBZJDHDSLA-UHFFFAOYSA-N 0.000 claims description 2
- XKYKSMAIJIVXDN-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-methylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2C)C=C(C=C3)C(=O)O)C=C1)F XKYKSMAIJIVXDN-UHFFFAOYSA-N 0.000 claims description 2
- GAXPSCFJNIDMDR-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-methyltriazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=NN2C)C=C(C=C3)C(=O)O)C=C1)F GAXPSCFJNIDMDR-UHFFFAOYSA-N 0.000 claims description 2
- FJNGXIOTJRWYGE-NRFANRHFSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C=C1)F FJNGXIOTJRWYGE-NRFANRHFSA-N 0.000 claims description 2
- BYYUOSXFZIZLGT-DEOSSOPVSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCCC2)C=C(C=C3)C(=O)O)C=C1)F BYYUOSXFZIZLGT-DEOSSOPVSA-N 0.000 claims description 2
- CGRPMZZQTGYYOE-HXUWFJFHSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(3R)-oxolan-3-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@@H]2COCC2)C=C(C=C3)C(=O)O)C=C1)F CGRPMZZQTGYYOE-HXUWFJFHSA-N 0.000 claims description 2
- WWOKCHZWAGJLHQ-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-4-fluoro-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CCOC)C(=C(C=C3)C(=O)O)F)C=C1)F WWOKCHZWAGJLHQ-UHFFFAOYSA-N 0.000 claims description 2
- XNNLCCDKBAIKHT-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)O)C=C1)F XNNLCCDKBAIKHT-UHFFFAOYSA-N 0.000 claims description 2
- MEILDZONVGDFNF-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[(3-ethyltriazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC2=CN=NN2CC)C=C(C=C3)C(=O)O)C=C1)F MEILDZONVGDFNF-UHFFFAOYSA-N 0.000 claims description 2
- UKUDXTCSFFALTE-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[(3-methylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2C)C=C(C=C3)C(=O)O)C=C1)F UKUDXTCSFFALTE-UHFFFAOYSA-N 0.000 claims description 2
- ONXBVBLWZIBJCL-NRFANRHFSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2C[C@H]2OCC2)C=C1)F ONXBVBLWZIBJCL-NRFANRHFSA-N 0.000 claims description 2
- WETGNQFNWZICPZ-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,2-oxazol-3-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=NOC=C2)C=C(C=C3)C(=O)O)C=C1)F WETGNQFNWZICPZ-UHFFFAOYSA-N 0.000 claims description 2
- WXVMPIKVKADUBX-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)imidazo[4,5-b]pyridine-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)O)N2CC=2OC=CN=2)C=C1)F WXVMPIKVKADUBX-UHFFFAOYSA-N 0.000 claims description 2
- HYBAKUMPISVZQP-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(oxetan-2-ylmethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-UHFFFAOYSA-N 0.000 claims description 2
- WQNQFKWZTAZBGZ-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)O)C=C1)F WQNQFKWZTAZBGZ-UHFFFAOYSA-N 0.000 claims description 2
- SUDUVYVOAWVFQI-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-ethyltriazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=NN2CC)C=C(C=C3)C(=O)O)C=C1)F SUDUVYVOAWVFQI-UHFFFAOYSA-N 0.000 claims description 2
- HUKCENNLWBEOOS-UHFFFAOYSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-methylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2C)C=C(C=C3)C(=O)O)C=C1)F HUKCENNLWBEOOS-UHFFFAOYSA-N 0.000 claims description 2
- HYBAKUMPISVZQP-XMMPIXPASA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2R)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-XMMPIXPASA-N 0.000 claims description 2
- KYAMEOCCRNSOEY-VWLOTQADSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCCC2)C=C(C=C3)C(=O)O)C=C1)F KYAMEOCCRNSOEY-VWLOTQADSA-N 0.000 claims description 2
- NINPGBYQOIGTQN-JOCHJYFZSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(3R)-oxolan-3-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@@H]2COCC2)C=C(C=C3)C(=O)O)C=C1)F NINPGBYQOIGTQN-JOCHJYFZSA-N 0.000 claims description 2
- NINPGBYQOIGTQN-QFIPXVFZSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(3S)-oxolan-3-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2COCC2)C=C(C=C3)C(=O)O)C=C1)F NINPGBYQOIGTQN-QFIPXVFZSA-N 0.000 claims description 2
- RPVGGZOBMUVKRF-RUZDIDTESA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2R)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@@H]2OCCC2)C=C(C=C3)C(=O)O)F)C=C1 RPVGGZOBMUVKRF-RUZDIDTESA-N 0.000 claims description 2
- QHRUSAYNQULGEA-DEOSSOPVSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)F)C=C1 QHRUSAYNQULGEA-DEOSSOPVSA-N 0.000 claims description 2
- RPVGGZOBMUVKRF-VWLOTQADSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCCC2)C=C(C=C3)C(=O)O)F)C=C1 RPVGGZOBMUVKRF-VWLOTQADSA-N 0.000 claims description 2
- AOAGOHODWHAPQT-UHFFFAOYSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C=C1 AOAGOHODWHAPQT-UHFFFAOYSA-N 0.000 claims description 2
- FWOZAWDCBQVUKK-AREMUKBSSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2R)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@@H]2OCCC2)C=C(C=C3)C(=O)O)C=C1 FWOZAWDCBQVUKK-AREMUKBSSA-N 0.000 claims description 2
- KWYDOKLBVSCOKI-VWLOTQADSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1 KWYDOKLBVSCOKI-VWLOTQADSA-N 0.000 claims description 2
- FWOZAWDCBQVUKK-SANMLTNESA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxolan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCCC2)C=C(C=C3)C(=O)O)C=C1 FWOZAWDCBQVUKK-SANMLTNESA-N 0.000 claims description 2
- NKNKXCQSWOHJQE-UHFFFAOYSA-N 2-[[4-[6-[(4-cyanophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-4-fluoro-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CCOC)C(=C(C=C3)C(=O)O)F)C=C1 NKNKXCQSWOHJQE-UHFFFAOYSA-N 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 claims 1
- 206010036049 Polycystic ovaries Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 abstract description 15
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical class C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 150000001556 benzimidazoles Chemical class 0.000 abstract description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 267
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 195
- 239000000203 mixture Substances 0.000 description 190
- 239000000243 solution Substances 0.000 description 157
- 235000019439 ethyl acetate Nutrition 0.000 description 133
- 239000000543 intermediate Substances 0.000 description 132
- 239000007787 solid Substances 0.000 description 131
- 230000002829 reductive effect Effects 0.000 description 130
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 105
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 81
- 238000005481 NMR spectroscopy Methods 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 71
- 125000000217 alkyl group Chemical group 0.000 description 66
- 239000011734 sodium Substances 0.000 description 60
- 239000012043 crude product Substances 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 49
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 47
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 46
- 125000001424 substituent group Chemical group 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 38
- 239000000460 chlorine Substances 0.000 description 38
- 239000000725 suspension Substances 0.000 description 36
- 238000001914 filtration Methods 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 35
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 35
- 239000002904 solvent Substances 0.000 description 35
- 239000012267 brine Substances 0.000 description 34
- 239000003921 oil Substances 0.000 description 34
- 235000019198 oils Nutrition 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 150000001412 amines Chemical class 0.000 description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 27
- 239000002585 base Substances 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000002253 acid Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 229910052801 chlorine Inorganic materials 0.000 description 23
- 125000001153 fluoro group Chemical group F* 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 125000004093 cyano group Chemical group *C#N 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000004808 supercritical fluid chromatography Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 229910052731 fluorine Inorganic materials 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 11
- 238000005859 coupling reaction Methods 0.000 description 11
- 239000013058 crude material Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 10
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 10
- 239000000010 aprotic solvent Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000012746 preparative thin layer chromatography Methods 0.000 description 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 150000004985 diamines Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 6
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- NPEIUNVTLXEOLT-UHFFFAOYSA-N 2-chloro-1,1,1-trimethoxyethane Chemical compound COC(CCl)(OC)OC NPEIUNVTLXEOLT-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- HYWFGBSBJHAXBE-UHFFFAOYSA-N methyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CC(N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)OC)C)C=C1)F HYWFGBSBJHAXBE-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XUZRWKWJKDCQNA-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1F XUZRWKWJKDCQNA-UHFFFAOYSA-N 0.000 description 4
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 4
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 108010019598 Liraglutide Proteins 0.000 description 4
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 229940045348 brown mixture Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 4
- 229950000991 ipragliflozin Drugs 0.000 description 4
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 229960002701 liraglutide Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000002184 metal Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- HYWFGBSBJHAXBE-LEWJYISDSA-N methyl 2-[[(2S,4R)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylate Chemical class ClC1=CC(=C(COC2=CC=CC(=N2)[C@H]2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)OC)C)C=C1)F HYWFGBSBJHAXBE-LEWJYISDSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000003586 protic polar solvent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003419 tautomerization reaction Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- MHGRIBXIKDJHKB-QHCPKHFHSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F MHGRIBXIKDJHKB-QHCPKHFHSA-N 0.000 description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 3
- 108010011459 Exenatide Proteins 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- QDEFNAHLCTUWAH-BYPYZUCNSA-N [(2s)-oxetan-2-yl]methanamine Chemical compound NC[C@@H]1CCO1 QDEFNAHLCTUWAH-BYPYZUCNSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960001713 canagliflozin Drugs 0.000 description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960003834 dapagliflozin Drugs 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960003345 empagliflozin Drugs 0.000 description 3
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 3
- 229950006535 ertugliflozin Drugs 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229950004994 meglitinide Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- YAWLZFBIZMMVLI-UHFFFAOYSA-N tert-butyl 4-(6-chloropyridin-2-yl)piperidine-1-carboxylate Chemical compound ClC1=CC=CC(=N1)C1CCN(CC1)C(=O)OC(C)(C)C YAWLZFBIZMMVLI-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- NTZXBJJNAKCVQO-BYPYZUCNSA-N (2S)-2-(azidomethyl)oxetane Chemical compound N(=[N+]=[N-])C[C@H]1OCC1 NTZXBJJNAKCVQO-BYPYZUCNSA-N 0.000 description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 2
- LMLDXXXZBRCPIP-NSHDSACASA-N (2s)-2-(phenylmethoxymethyl)oxetane Chemical compound C([C@H]1OCC1)OCC1=CC=CC=C1 LMLDXXXZBRCPIP-NSHDSACASA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- YMJMSYXLHSSGTP-UHFFFAOYSA-N 1,3-oxazol-2-ylmethanamine;hydrochloride Chemical class Cl.NCC1=NC=CO1 YMJMSYXLHSSGTP-UHFFFAOYSA-N 0.000 description 2
- VRLNOXRCNGNLDC-UHFFFAOYSA-N 1-O-tert-butyl 4-O-methyl 4-(6-chloropyridin-2-yl)piperidine-1,4-dicarboxylate Chemical compound ClC1=CC=CC(=N1)C1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)OC VRLNOXRCNGNLDC-UHFFFAOYSA-N 0.000 description 2
- JKVOXNTXYMXDHN-UHFFFAOYSA-N 2,3,5-trifluoropyridine Chemical compound FC1=CN=C(F)C(F)=C1 JKVOXNTXYMXDHN-UHFFFAOYSA-N 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 2
- YRWRWKIQDLRSCA-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-3,6-difluoropyridine Chemical compound ClC1=CC(=C(COC2=NC(=CC=C2F)F)C=C1)F YRWRWKIQDLRSCA-UHFFFAOYSA-N 0.000 description 2
- RCWADFUIDXOIQD-UHFFFAOYSA-N 2-[4-(6-chloropyridin-2-yl)piperidin-1-yl]acetic acid Chemical compound ClC1=CC=CC(=N1)C1CCN(CC1)CC(=O)O RCWADFUIDXOIQD-UHFFFAOYSA-N 0.000 description 2
- DRKKUKDHSWFCNH-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-(trifluoromethyl)piperazin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)N2CC(N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C(F)(F)F)C=C1)F DRKKUKDHSWFCNH-UHFFFAOYSA-N 0.000 description 2
- BGGOPJONUKJHSL-QHCPKHFHSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)F)C=C1)F BGGOPJONUKJHSL-QHCPKHFHSA-N 0.000 description 2
- DVJXGNPUDMVFRQ-UHFFFAOYSA-N 2-bromo-n-methyl-5-nitropyridin-4-amine Chemical compound CNC1=CC(Br)=NC=C1[N+]([O-])=O DVJXGNPUDMVFRQ-UHFFFAOYSA-N 0.000 description 2
- YIPAQVRDEANTRW-UHFFFAOYSA-N 2-chloro-6-[(4-chloro-2-fluorophenyl)methoxy]pyridine Chemical compound ClC1=NC(=CC=C1)OCC1=C(C=C(C=C1)Cl)F YIPAQVRDEANTRW-UHFFFAOYSA-N 0.000 description 2
- JFMYTUHHVKNCIA-UHFFFAOYSA-N 2-chloro-6-piperidin-4-ylpyridine hydrochloride Chemical compound Cl.Clc1cccc(n1)C1CCNCC1 JFMYTUHHVKNCIA-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- GAIRPXUHDUDFHF-UHFFFAOYSA-N 4-[(3-fluoro-6-piperidin-4-ylpyridin-2-yl)oxymethyl]benzonitrile 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.Fc1ccc(nc1OCc1ccc(cc1)C#N)C1CCNCC1 GAIRPXUHDUDFHF-UHFFFAOYSA-N 0.000 description 2
- BSCXJGYBFUSMSF-UHFFFAOYSA-N 4-[(6-chloropyridin-2-yl)oxymethyl]-3-fluorobenzonitrile Chemical compound ClC1=CC=CC(=N1)OCC1=C(C=C(C#N)C=C1)F BSCXJGYBFUSMSF-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- FTQWWKMNAOBXKN-UHFFFAOYSA-N 5-bromo-3-N-(2-methoxyethyl)pyridine-2,3-diamine Chemical compound BrC=1C=C(C(=NC=1)N)NCCOC FTQWWKMNAOBXKN-UHFFFAOYSA-N 0.000 description 2
- NCHALYMABWDRAW-UHFFFAOYSA-N 6-bromo-4-N-methylpyridine-3,4-diamine hydrochloride Chemical compound Cl.CNc1cc(Br)ncc1N NCHALYMABWDRAW-UHFFFAOYSA-N 0.000 description 2
- QPUXFBYDNRQUER-UHFFFAOYSA-N 6-chloro-2-n-methylpyridine-2,3-diamine Chemical compound CNC1=NC(Cl)=CC=C1N QPUXFBYDNRQUER-UHFFFAOYSA-N 0.000 description 2
- WMPMXUCWDZXMEW-UHFFFAOYSA-N 6-chloro-5-nitropicolinic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(Cl)=N1 WMPMXUCWDZXMEW-UHFFFAOYSA-N 0.000 description 2
- XBUWSEJQFZDJAZ-UHFFFAOYSA-N 6-chloro-n-methyl-3-nitropyridin-2-amine Chemical compound CNC1=NC(Cl)=CC=C1[N+]([O-])=O XBUWSEJQFZDJAZ-UHFFFAOYSA-N 0.000 description 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 102000012234 Cannabinoid receptor type 1 Human genes 0.000 description 2
- 108050002726 Cannabinoid receptor type 1 Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- QNAMWTDEWRUVFT-NWDGAFQWSA-N ClC1=CC=CC(=N1)[C@H]1[C@H](CN(CC1)C(=O)OC(C)(C)C)C Chemical compound ClC1=CC=CC(=N1)[C@H]1[C@H](CN(CC1)C(=O)OC(C)(C)C)C QNAMWTDEWRUVFT-NWDGAFQWSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- PNIHHHKOZPCYQK-JTQLQIEISA-N FC=1C(=NC(=CC=1)F)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C Chemical compound FC=1C(=NC(=CC=1)F)N1C[C@@H](N(CC1)C(=O)OC(C)(C)C)C PNIHHHKOZPCYQK-JTQLQIEISA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 2
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 description 2
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 2
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- VCPIENOFTZQXPZ-UHFFFAOYSA-N N-(2-amino-5-bromopyridin-3-yl)-2-methoxyacetamide Chemical compound NC1=NC=C(C=C1NC(COC)=O)Br VCPIENOFTZQXPZ-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 2
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 2
- QLXKHBNJTPICNF-QMCAAQAGSA-N Sergliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- NALKUTSPQGNISH-YFKPBYRVSA-N [(2S)-oxetan-2-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OC[C@H]1OCC1 NALKUTSPQGNISH-YFKPBYRVSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229960004733 albiglutide Drugs 0.000 description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 2
- 229960001667 alogliptin Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 108010005794 dulaglutide Proteins 0.000 description 2
- 229960005175 dulaglutide Drugs 0.000 description 2
- 229950003693 dutogliptin Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- ARHGUWASVXEVPL-UHFFFAOYSA-N ethyl 2-[4-(6-chloropyridin-2-yl)piperidin-1-yl]acetate Chemical compound ClC1=CC=CC(=N1)C1CCN(CC1)CC(=O)OCC ARHGUWASVXEVPL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 230000009229 glucose formation Effects 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 102000056448 human GLP1R Human genes 0.000 description 2
- 102000004241 human proIslet peptide Human genes 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960002397 linagliptin Drugs 0.000 description 2
- 229960001093 lixisenatide Drugs 0.000 description 2
- 108010004367 lixisenatide Proteins 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 2
- 229950007685 lobeglitazone Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- HJWMRMWTNAROEM-UHFFFAOYSA-N methyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-methylimidazo[4,5-b]pyridine-5-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)OC)N2C)C=C1)F HJWMRMWTNAROEM-UHFFFAOYSA-N 0.000 description 2
- OOEWPNGKWZWOTQ-UHFFFAOYSA-N methyl 3-(methylamino)-4-nitrobenzoate Chemical compound CNC1=CC(C(=O)OC)=CC=C1[N+]([O-])=O OOEWPNGKWZWOTQ-UHFFFAOYSA-N 0.000 description 2
- NLMYAAYZFGSGIT-UHFFFAOYSA-N methyl 3-[(2-hydroxycyclopentyl)methylamino]-4-nitrobenzoate Chemical compound OC1C(CCC1)CNC=1C=C(C(=O)OC)C=CC=1[N+](=O)[O-] NLMYAAYZFGSGIT-UHFFFAOYSA-N 0.000 description 2
- SAHVLXFHXAHSAN-UHFFFAOYSA-N methyl 3-[(3-methylimidazol-4-yl)methylamino]-4-nitrobenzoate Chemical compound CN1C=NC=C1CNC=1C=C(C(=O)OC)C=CC=1[N+](=O)[O-] SAHVLXFHXAHSAN-UHFFFAOYSA-N 0.000 description 2
- GSFLPGVBPFPGNK-UHFFFAOYSA-N methyl 4-amino-3-[(3-methylimidazol-4-yl)methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CN1C GSFLPGVBPFPGNK-UHFFFAOYSA-N 0.000 description 2
- YUBBGZUEOCQFQQ-UHFFFAOYSA-N methyl 4-nitro-3-(1,3-oxazol-5-ylmethylamino)benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CO1 YUBBGZUEOCQFQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
- 229960001601 obeticholic acid Drugs 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- PQZJTHGEFIQMCO-UHFFFAOYSA-N oxetan-2-ylmethanol Chemical compound OCC1CCO1 PQZJTHGEFIQMCO-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 108700027806 rGLP-1 Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 108010060325 semaglutide Proteins 0.000 description 2
- 229950011186 semaglutide Drugs 0.000 description 2
- 229950000378 sergliflozin etabonate Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- QNAMWTDEWRUVFT-RYUDHWBXSA-N tert-butyl (3R,4S)-4-(6-chloropyridin-2-yl)-3-methylpiperidine-1-carboxylate Chemical compound ClC1=CC=CC(=N1)[C@@H]1[C@H](CN(CC1)C(=O)OC(C)(C)C)C QNAMWTDEWRUVFT-RYUDHWBXSA-N 0.000 description 2
- IDJUYUBLTQMLJO-UHFFFAOYSA-N tert-butyl 2-(chloromethyl)-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1CC=1OC=CN=1)C=C(C=C2)C(=O)OC(C)(C)C IDJUYUBLTQMLJO-UHFFFAOYSA-N 0.000 description 2
- QVFMXPSRCKFQTC-UHFFFAOYSA-N tert-butyl 4-(5-fluoro-1-oxidopyridin-1-ium-2-yl)piperidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C1=[N+](C=C(C=C1)F)[O-] QVFMXPSRCKFQTC-UHFFFAOYSA-N 0.000 description 2
- LBKVIFRVNIAOEI-UHFFFAOYSA-N tert-butyl 4-(5-fluoropyridin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound FC=1C=CC(=NC=1)C=1CCN(CC=1)C(=O)OC(C)(C)C LBKVIFRVNIAOEI-UHFFFAOYSA-N 0.000 description 2
- GDDKKSBUYQFDQA-UHFFFAOYSA-N tert-butyl 4-(5-fluoropyridin-2-yl)piperidine-1-carboxylate Chemical compound FC=1C=CC(=NC=1)C1CCN(CC1)C(=O)OC(C)(C)C GDDKKSBUYQFDQA-UHFFFAOYSA-N 0.000 description 2
- WPMIJUDOIBEJLG-UHFFFAOYSA-N tert-butyl 4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperazine-1-carboxylate Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)C(=O)OC(C)(C)C)C=C1)F WPMIJUDOIBEJLG-UHFFFAOYSA-N 0.000 description 2
- XMSDQXCPSLTGGT-UHFFFAOYSA-N tert-butyl 4-amino-3-(1,3-oxazol-2-ylmethylamino)benzoate Chemical compound NC1=C(C=C(C(=O)OC(C)(C)C)C=C1)NCC=1OC=CN=1 XMSDQXCPSLTGGT-UHFFFAOYSA-N 0.000 description 2
- FEEAVMNWGHKOAN-UHFFFAOYSA-N tert-butyl 4-nitro-3-(1,3-oxazol-2-ylmethylamino)benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC(C)(C)C)C=C1)NCC=1OC=CN=1 FEEAVMNWGHKOAN-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QNYBOILAKBSWFG-SNVBAGLBSA-N (2s)-2-(phenylmethoxymethyl)oxirane Chemical compound C([C@H]1OC1)OCC1=CC=CC=C1 QNYBOILAKBSWFG-SNVBAGLBSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- JMVGTUJLDTZQFC-UHFFFAOYSA-N (3-ethylimidazol-4-yl)methanamine Chemical compound CCN1C=NC=C1CN JMVGTUJLDTZQFC-UHFFFAOYSA-N 0.000 description 1
- PYAQTQXFMQWCHQ-UHFFFAOYSA-N (3-methylimidazol-4-yl)methanamine Chemical compound CN1C=NC=C1CN PYAQTQXFMQWCHQ-UHFFFAOYSA-N 0.000 description 1
- OBCDLQWFMWQSLR-MERQFXBCSA-N (3S)-1-[6-[(4-chloro-2-fluorophenyl)methoxy]-3-fluoropyridin-2-yl]-3-methylpiperazine hydrochloride Chemical compound Cl.C[C@H]1CN(CCN1)c1nc(OCc2ccc(Cl)cc2F)ccc1F OBCDLQWFMWQSLR-MERQFXBCSA-N 0.000 description 1
- HJCKPHJFKQAUBR-MERQFXBCSA-N (3S)-1-[6-[(4-chloro-2-fluorophenyl)methoxy]-5-fluoropyridin-2-yl]-3-methylpiperazine hydrochloride Chemical compound Cl.C[C@H]1CN(CCN1)c1ccc(F)c(OCc2ccc(Cl)cc2F)n1 HJCKPHJFKQAUBR-MERQFXBCSA-N 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 1
- HDHDTKMUACZDAA-PHNIDTBTSA-N (4r,7s,10s,13r,16s,19r,22r)-22-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1h-imidazol-5-ylmethyl)-7-(1h-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20 Chemical compound C([C@@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](C(N[C@@H](CC=2N=CNC=2)C(=O)N1)=O)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(N)=O)C1=CC=CC=C1 HDHDTKMUACZDAA-PHNIDTBTSA-N 0.000 description 1
- JHLIGYPHPBLDDL-UHFFFAOYSA-N (5-pyridin-3-ylthiophen-2-yl)methanamine Chemical compound S1C(CN)=CC=C1C1=CC=CN=C1 JHLIGYPHPBLDDL-UHFFFAOYSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- ZPIDZCBCCUTEEI-UHFFFAOYSA-N 1,3-oxazol-5-ylmethanamine Chemical compound NCC1=CN=CO1 ZPIDZCBCCUTEEI-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- RZZGFCFQBVRQSX-UHFFFAOYSA-N 2,4-dibromo-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Br)C=C1Br RZZGFCFQBVRQSX-UHFFFAOYSA-N 0.000 description 1
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 1
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 1
- GWSHKGVOFSMTLQ-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-6-(2-methylpiperidin-4-yl)pyridine Chemical compound ClC1=CC(=C(COC2=NC(=CC=C2)C2CC(NCC2)C)C=C1)F GWSHKGVOFSMTLQ-UHFFFAOYSA-N 0.000 description 1
- ZNTXEZPIOPSLHR-SLHAJLBXSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-6-[(3R,4R)-3-fluoropiperidin-4-yl]pyridine hydrochloride Chemical compound Cl.F[C@H]1CNCC[C@@H]1c1cccc(OCc2ccc(Cl)cc2F)n1 ZNTXEZPIOPSLHR-SLHAJLBXSA-N 0.000 description 1
- DAXBKIDWWYJOAC-SBKWZQTDSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-6-[(3R,4R)-3-methylpiperidin-4-yl]pyridine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CNCC[C@H]1c1cccc(OCc2ccc(Cl)cc2F)n1 DAXBKIDWWYJOAC-SBKWZQTDSA-N 0.000 description 1
- DAXBKIDWWYJOAC-NXCSSKFKSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-6-[(3R,4S)-3-methylpiperidin-4-yl]pyridine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C[C@H]1CNCC[C@@H]1c1cccc(OCc2ccc(Cl)cc2F)n1 DAXBKIDWWYJOAC-NXCSSKFKSA-N 0.000 description 1
- HDJHLDDLMSUKRV-UHFFFAOYSA-N 2-[(4-chloro-2-fluorophenyl)methoxy]-6-piperidin-4-ylpyridine 4-methylbenzenesulfonic acid Chemical compound Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O.Fc1cc(Cl)ccc1COc1cccc(n1)C1CCNCC1 HDJHLDDLMSUKRV-UHFFFAOYSA-N 0.000 description 1
- ZZWWXIBKLBMSCS-FQEVSTJZSA-N 2-[1-[(2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid Chemical compound COC1=CC=CC=C1[C@@H](OC1CCOCC1)CN1C(=O)N(C(C)(C)C(O)=O)C(=O)C2=C1SC(C=1OC=CN=1)=C2C ZZWWXIBKLBMSCS-FQEVSTJZSA-N 0.000 description 1
- ZGCZGXNWXCZJPF-UHFFFAOYSA-N 2-[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]acetic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC(=O)O)C=C1)F ZGCZGXNWXCZJPF-UHFFFAOYSA-N 0.000 description 1
- CNIFOADZUXVJPB-UHFFFAOYSA-N 2-[4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]acetic acid Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC(=O)O)F)C=C1 CNIFOADZUXVJPB-UHFFFAOYSA-N 0.000 description 1
- GTMWLWDYOZIYDR-FIWHBWSRSA-N 2-[[(2R)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound COCCn1c(CN2CCC(C[C@H]2C)c2cccc(OCc3ccc(Cl)cc3F)n2)nc2ccc(cc12)C(O)=O GTMWLWDYOZIYDR-FIWHBWSRSA-N 0.000 description 1
- ZQQMPHJMAHUMQA-AVRDEDQJSA-N 2-[[(2S)-4-[6-[(2,4-difluorophenyl)methoxy]-5-fluoropyridin-2-yl]-2-methylpiperazin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound FC1=C(COC2=C(C=CC(=N2)N2C[C@@H](N(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C)F)C=CC(=C1)F ZQQMPHJMAHUMQA-AVRDEDQJSA-N 0.000 description 1
- GTMWLWDYOZIYDR-VQTJNVASSA-N 2-[[(2S,4R)-4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]-2-methylpiperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)[C@H]2C[C@@H](N(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)O)C)C=C1)F GTMWLWDYOZIYDR-VQTJNVASSA-N 0.000 description 1
- PPLLIJPBNNGLRT-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-1-(2-methoxyethyl)imidazo[4,5-b]pyridine-6-carboxylic acid hydrochloride Chemical compound Cl.COCCn1c(CN2CCC(CC2)c2cccc(OCc3ccc(Cl)cc3F)n2)nc2ncc(cc12)C(O)=O PPLLIJPBNNGLRT-UHFFFAOYSA-N 0.000 description 1
- RCQYGXCXXXURDS-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-1-methylimidazo[4,5-c]pyridine-6-carboxylic acid Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC=2N(C3=C(C=NC(=C3)C(=O)O)N=2)C)C=C1)F RCQYGXCXXXURDS-UHFFFAOYSA-N 0.000 description 1
- QTDCQHRTOIWLQZ-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-methylbenzimidazole-5-carboxylic acid hydrochloride Chemical compound Cl.Cn1c(CN2CCC(CC2)c2cccc(OCc3ccc(Cl)cc3F)n2)nc2ccc(cc12)C(O)=O QTDCQHRTOIWLQZ-UHFFFAOYSA-N 0.000 description 1
- KXQNLKQVGCIGFO-UHFFFAOYSA-N 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-methylimidazo[4,5-b]pyridine-5-carboxylic acid hydrochloride Chemical compound Cl.Cn1c(CN2CCC(CC2)c2cccc(OCc3ccc(Cl)cc3F)n2)nc2ccc(nc12)C(O)=O KXQNLKQVGCIGFO-UHFFFAOYSA-N 0.000 description 1
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 1
- UIEVSGOVFXWCIK-UHFFFAOYSA-N 2-chloro-6-methyl-3-nitropyridine Chemical compound CC1=CC=C([N+]([O-])=O)C(Cl)=N1 UIEVSGOVFXWCIK-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- MLFBJQDSMCXSHS-UHFFFAOYSA-M 3-(2-methoxyethyl)-2-[[4-[6-[(4-methylphenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]benzimidazole-5-carboxylate Chemical compound COCCn1c(CN2CCC(CC2)c2cccc(OCc3ccc(C)cc3)n2)nc2ccc(cc12)C([O-])=O MLFBJQDSMCXSHS-UHFFFAOYSA-M 0.000 description 1
- WTWOJTCOPMKHQH-UHFFFAOYSA-N 3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylic acid Chemical compound C(C)N1C=NC=C1CN1C=NC2=C1C=C(C=C2)C(=O)O WTWOJTCOPMKHQH-UHFFFAOYSA-N 0.000 description 1
- YGAURRAHPYQHDC-UHFFFAOYSA-N 3-fluoro-4-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=C(C#N)C=C1F YGAURRAHPYQHDC-UHFFFAOYSA-N 0.000 description 1
- WVKIEEVFGCAMFO-UHFFFAOYSA-N 3-fluoro-4-[(6-piperazin-1-ylpyridin-2-yl)oxymethyl]benzonitrile Chemical compound FC1=C(COC2=CC=CC(=N2)N2CCNCC2)C=CC(=C1)C#N WVKIEEVFGCAMFO-UHFFFAOYSA-N 0.000 description 1
- FUFAJLZCHQLGTN-UHFFFAOYSA-N 3-fluoro-4-[(6-piperazin-1-ylpyridin-2-yl)oxymethyl]benzonitrile dihydrochloride Chemical compound Cl.Cl.FC=1C=C(C#N)C=CC1COC1=NC(=CC=C1)N1CCNCC1 FUFAJLZCHQLGTN-UHFFFAOYSA-N 0.000 description 1
- GZLJOIOOWNBVMD-UHFFFAOYSA-N 3-fluoro-4-[(6-piperidin-4-ylpyridin-2-yl)oxymethyl]benzonitrile 4-methylbenzenesulfonic acid Chemical compound Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O.Fc1cc(ccc1COc1cccc(n1)C1CCNCC1)C#N GZLJOIOOWNBVMD-UHFFFAOYSA-N 0.000 description 1
- WVZBIQSKLXJFNX-UHFFFAOYSA-N 3-fluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 WVZBIQSKLXJFNX-UHFFFAOYSA-N 0.000 description 1
- ICFURHQAHRYUKG-UHFFFAOYSA-N 3-methyl-2-[[4-(6-phenylmethoxypyridin-2-yl)piperidin-1-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC1=CC=CC(=N1)C1CCN(CC1)CC1=NC2=C(N1C)C=C(C=C2)C(=O)O ICFURHQAHRYUKG-UHFFFAOYSA-N 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- BUVVJIGULSJYLF-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCN(C(O)=O)CC1 BUVVJIGULSJYLF-UHFFFAOYSA-N 0.000 description 1
- SBCYMHNJXRVZGY-UHFFFAOYSA-N 4-(6-chloropyridin-2-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C(=O)O)C1=NC(=CC=C1)Cl SBCYMHNJXRVZGY-UHFFFAOYSA-N 0.000 description 1
- RFQQMVDUJGNVDB-UHFFFAOYSA-N 4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-3-ol 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC1CNCCC1c1cccc(OCc2ccc(Cl)cc2F)n1 RFQQMVDUJGNVDB-UHFFFAOYSA-N 0.000 description 1
- KHATZJGPRHFUCS-UHFFFAOYSA-N 4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-3-ol hydrochloride Chemical compound Cl.OC1CNCCC1c1cccc(OCc2ccc(Cl)cc2F)n1 KHATZJGPRHFUCS-UHFFFAOYSA-N 0.000 description 1
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 description 1
- HILNGYKHDWUMCC-UHFFFAOYSA-N 4-amino-3-(1,3-oxazol-5-ylmethylamino)benzoic acid Chemical compound Nc1ccc(cc1NCc1cnco1)C(O)=O HILNGYKHDWUMCC-UHFFFAOYSA-N 0.000 description 1
- XAASLEJRGFPHEV-UHFFFAOYSA-N 4-cyanobenzyl alcohol Chemical compound OCC1=CC=C(C#N)C=C1 XAASLEJRGFPHEV-UHFFFAOYSA-N 0.000 description 1
- KMTDMTZBNYGUNX-UHFFFAOYSA-N 4-methylbenzyl alcohol Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- DNMDTVJSXSMYGZ-UHFFFAOYSA-N 5-bromo-3-N,6-dimethylpyridine-2,3-diamine Chemical compound BrC=1C=C(C(=NC=1C)N)NC DNMDTVJSXSMYGZ-UHFFFAOYSA-N 0.000 description 1
- IEZBJIKJXNNYFC-UHFFFAOYSA-N 5-bromo-3-n-methylpyridine-2,3-diamine Chemical compound CNC1=CC(Br)=CN=C1N IEZBJIKJXNNYFC-UHFFFAOYSA-N 0.000 description 1
- YRGMYJUKFJPNPD-UHFFFAOYSA-N 5-bromopyridine-2,3-diamine Chemical compound NC1=CC(Br)=CN=C1N YRGMYJUKFJPNPD-UHFFFAOYSA-N 0.000 description 1
- SIMNREKTPYENRF-UHFFFAOYSA-N 5-chloro-2-(chloromethyl)-3-methylimidazo[4,5-b]pyridine Chemical compound ClC1=CC=C2C(=N1)N(C(=N2)CCl)C SIMNREKTPYENRF-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KBJNPLZAHROVHA-UHFFFAOYSA-N 6-bromo-2-(chloromethyl)-1-(2-methoxyethyl)imidazo[4,5-b]pyridine Chemical compound BrC=1C=C2C(=NC=1)N=C(N2CCOC)CCl KBJNPLZAHROVHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- XOISACZZLODXOF-UHFFFAOYSA-N BrC1=CC(=C(C=N1)NC(CN1CCC(CC1)C1=NC(=CC=C1)OCC1=C(C=C(C=C1)Cl)F)=O)NC Chemical compound BrC1=CC(=C(C=N1)NC(CN1CCC(CC1)C1=NC(=CC=C1)OCC1=C(C=C(C=C1)Cl)F)=O)NC XOISACZZLODXOF-UHFFFAOYSA-N 0.000 description 1
- QCHSMMCSFBPGLM-VWLOTQADSA-N C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC)C=C1)F Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC)C=C1)F QCHSMMCSFBPGLM-VWLOTQADSA-N 0.000 description 1
- FEHSOWJDAZSQDN-QHCPKHFHSA-N C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)OC)N2C[C@H]2OCC2)C=C1)F Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC=3C(=NC(=CC=3)C(=O)OC)N2C[C@H]2OCC2)C=C1)F FEHSOWJDAZSQDN-QHCPKHFHSA-N 0.000 description 1
- UVWRRKLEOGHBSG-DEOSSOPVSA-N C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC)C=C1)F Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)N2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)OC)C=C1)F UVWRRKLEOGHBSG-DEOSSOPVSA-N 0.000 description 1
- APYNGJJGZSZDAC-AWEZNQCLSA-N C(C)(C)(C)N1[C@H](CN(CC1)C1=NC(=CC=C1F)OCC1=C(C=C(C=C1)Cl)F)C Chemical compound C(C)(C)(C)N1[C@H](CN(CC1)C1=NC(=CC=C1F)OCC1=C(C=C(C=C1)Cl)F)C APYNGJJGZSZDAC-AWEZNQCLSA-N 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- CQIIUNNTJUOOFC-AWEZNQCLSA-N ClC1=CC(=C(COC2=C(C=CC(=N2)N2C[C@@H](N(CC2)C(=O)OC(C)(C)C)C)F)C=C1)F Chemical compound ClC1=CC(=C(COC2=C(C=CC(=N2)N2C[C@@H](N(CC2)C(=O)OC(C)(C)C)C)F)C=C1)F CQIIUNNTJUOOFC-AWEZNQCLSA-N 0.000 description 1
- CBCQNNJBKMKMLC-WMZOPIPTSA-N ClC1=CC(=C(COC2=CC=CC(=N2)[C@@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)F)C=C1)F Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)[C@@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)F)C=C1)F CBCQNNJBKMKMLC-WMZOPIPTSA-N 0.000 description 1
- QKBUGTBVTNUGFO-APWZRJJASA-N ClC1=CC(=C(COC2=CC=CC(=N2)[C@@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)O)C=C1)F Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)[C@@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)O)C=C1)F QKBUGTBVTNUGFO-APWZRJJASA-N 0.000 description 1
- QKBUGTBVTNUGFO-LPHOPBHVSA-N ClC1=CC(=C(COC2=CC=CC(=N2)[C@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)O)C=C1)F Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)[C@H]2[C@H](CN(CC2)C(=O)OC(C)(C)C)O)C=C1)F QKBUGTBVTNUGFO-LPHOPBHVSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 101000785259 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT2 Proteins 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 101150108864 Ffar1 gene Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 208000036391 Genetic obesity Diseases 0.000 description 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 description 1
- 102220543450 Glucagon-like peptide 1 receptor_G168S_mutation Human genes 0.000 description 1
- 102220543451 Glucagon-like peptide 1 receptor_L260F_mutation Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 238000003057 HTRF cAMP Detection Kit Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 229940119490 Ketohexokinase inhibitor Drugs 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 101150113964 MPK5 gene Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102100026009 NF-kappa-B inhibitor zeta Human genes 0.000 description 1
- 101710115530 NF-kappa-B inhibitor zeta Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229940125818 PF-05221304 Drugs 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 108700027412 Pegbelfermin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 102000015925 Proto-oncogene Mas Human genes 0.000 description 1
- 108050004181 Proto-oncogene Mas Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108091006614 SLC10A2 Proteins 0.000 description 1
- 108091006277 SLC5A1 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000033489 Syndromic obesity Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KPWYNAGOBXLMSE-UHFFFAOYSA-N Tipelukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1SCCCOC1=CC=C(C(C)=O)C(OCCCC(O)=O)=C1CCC KPWYNAGOBXLMSE-UHFFFAOYSA-N 0.000 description 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 101100264077 Xenopus laevis wrn gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- QJWJPMLDQYEPPW-AUKZVGPFSA-N aclimostat Chemical compound O1CCN(CC1)CCC1CN(C1)C(=O)O[C@H]1[C@H]([C@@H]([C@@]2(CO2)CC1)[C@]1(O[C@@H]1CC=C(C)C)C)OC QJWJPMLDQYEPPW-AUKZVGPFSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229950010663 balaglitazone Drugs 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- ZEZFKUBILQRZCK-MJSCXXSSSA-N beloranib Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=2C=CC(OCCN(C)C)=CC=2)C[C@@]21CO2 ZEZFKUBILQRZCK-MJSCXXSSSA-N 0.000 description 1
- 229950009345 beloranib Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- 229940047123 bupropion and naltrexone Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- ATZQZZAXOPPAAQ-UHFFFAOYSA-M caesium formate Chemical compound [Cs+].[O-]C=O ATZQZZAXOPPAAQ-UHFFFAOYSA-M 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000005753 chloropyridines Chemical class 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DIBHLCJAJIKHGB-UHFFFAOYSA-N dec-5-ene Chemical compound [CH2]CCCC=CCCCC DIBHLCJAJIKHGB-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950000234 emricasan Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 229950009769 etabonate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NAOJPOKYWDUFFN-UHFFFAOYSA-N ethyl 2-[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]acetate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC(=O)OCC)C=C1)F NAOJPOKYWDUFFN-UHFFFAOYSA-N 0.000 description 1
- ZRFXWAWAOBWGQY-UHFFFAOYSA-N ethyl 2-[4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidin-1-yl]acetate Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)CC(=O)OCC)F)C=C1 ZRFXWAWAOBWGQY-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- WZSLHFLUNJMFSS-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-(2-methoxyethyl)benzimidazole-5-carboxylate hydrochloride Chemical compound Cl.COCCn1c(CCl)nc2ccc(cc12)C(=O)OC WZSLHFLUNJMFSS-UHFFFAOYSA-N 0.000 description 1
- IXBZCNQTENPZQY-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-[(3-methylimidazol-4-yl)methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1CC1=CN=CN1C)C=C(C=C2)C(=O)OC IXBZCNQTENPZQY-UHFFFAOYSA-N 0.000 description 1
- SLQIJFSQRNXACV-JTQLQIEISA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylate Chemical compound ClCC1=NC2=C(N1C[C@H]1OCC1)C=C(C=C2)C(=O)OC SLQIJFSQRNXACV-JTQLQIEISA-N 0.000 description 1
- YSLWOAWEVXQWPB-QMMMGPOBSA-N methyl 2-(chloromethyl)-3-[[(2S)-oxetan-2-yl]methyl]imidazo[4,5-b]pyridine-5-carboxylate Chemical compound ClCC1=NC=2C(=NC(=CC=2)C(=O)OC)N1C[C@H]1OCC1 YSLWOAWEVXQWPB-QMMMGPOBSA-N 0.000 description 1
- XDSCPFNHJYZTNS-UHFFFAOYSA-N methyl 2-(chloromethyl)-3-methylbenzimidazole-5-carboxylate Chemical compound ClCC=1N(C2=C(N=1)C=CC(=C2)C(=O)OC)C XDSCPFNHJYZTNS-UHFFFAOYSA-N 0.000 description 1
- LIGBAJISKSITNJ-UHFFFAOYSA-N methyl 2-[[4-(6-chloropyridin-2-yl)piperidin-1-yl]methyl]-3-methylbenzimidazole-5-carboxylate Chemical compound ClC1=CC=CC(=N1)C1CCN(CC1)CC1=NC2=C(N1C)C=C(C=C2)C(=O)OC LIGBAJISKSITNJ-UHFFFAOYSA-N 0.000 description 1
- RLQLXLMKKACEMW-UHFFFAOYSA-N methyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(2-methoxyethyl)benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CCOC)C=C(C=C3)C(=O)OC)C=C1)F RLQLXLMKKACEMW-UHFFFAOYSA-N 0.000 description 1
- HBXZKECOUPSICR-UHFFFAOYSA-N methyl 3-(2-methoxyethyl)-2-[[2-(trifluoromethyl)piperazin-1-yl]methyl]benzimidazole-5-carboxylate Chemical compound COCCN1C(=NC2=C1C=C(C=C2)C(=O)OC)CN1C(CNCC1)C(F)(F)F HBXZKECOUPSICR-UHFFFAOYSA-N 0.000 description 1
- VYVNYHWMZHHNJP-UHFFFAOYSA-N methyl 3-(2-methoxyethyl)-2-[[4-(6-oxo-1H-pyridin-2-yl)piperidin-1-yl]methyl]benzimidazole-5-carboxylate Chemical compound COCCN1C(=NC2=C1C=C(C=C2)C(=O)OC)CN1CCC(CC1)C=1NC(C=CC=1)=O VYVNYHWMZHHNJP-UHFFFAOYSA-N 0.000 description 1
- BQZZLOUIHVCKQS-UHFFFAOYSA-N methyl 3-(2-methoxyethyl)-2-[[4-[(2-methylpropan-2-yl)oxycarbonyl]-2-(trifluoromethyl)piperazin-1-yl]methyl]benzimidazole-5-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC(N(CC1)CC1=NC2=C(N1CCOC)C=C(C=C2)C(=O)OC)C(F)(F)F BQZZLOUIHVCKQS-UHFFFAOYSA-N 0.000 description 1
- HCIREWNLXZXGFU-UHFFFAOYSA-N methyl 3-(2-methoxyethylamino)-4-nitrobenzoate Chemical compound COCCNC=1C=C(C(=O)OC)C=CC=1[N+](=O)[O-] HCIREWNLXZXGFU-UHFFFAOYSA-N 0.000 description 1
- XSTSQVIOIDKUGV-UHFFFAOYSA-N methyl 3-[(2-methoxycyclopentyl)methylamino]-4-nitrobenzoate Chemical compound COC1C(CCC1)CNC=1C=C(C(=O)OC)C=CC=1[N+](=O)[O-] XSTSQVIOIDKUGV-UHFFFAOYSA-N 0.000 description 1
- OPETTYYAVSSKOH-UHFFFAOYSA-N methyl 3-methyl-2-[[4-(6-phenylmethoxypyridin-2-yl)piperidin-1-yl]methyl]benzimidazole-5-carboxylate Chemical compound C(C1=CC=CC=C1)OC1=CC=CC(=N1)C1CCN(CC1)CC1=NC2=C(N1C)C=C(C=C2)C(=O)OC OPETTYYAVSSKOH-UHFFFAOYSA-N 0.000 description 1
- LOKYZYLRFLWOEU-UHFFFAOYSA-N methyl 4-amino-3-(1,3-oxazol-5-ylmethylamino)benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CO1 LOKYZYLRFLWOEU-UHFFFAOYSA-N 0.000 description 1
- YELUKQRRBLOBKP-UHFFFAOYSA-N methyl 4-amino-3-(2-methoxyethylamino)benzoate Chemical compound COCCNC1=CC(C(=O)OC)=CC=C1N YELUKQRRBLOBKP-UHFFFAOYSA-N 0.000 description 1
- VWGIBJGZLCERFV-UHFFFAOYSA-N methyl 4-amino-3-(methylamino)benzoate Chemical compound CNC1=CC(C(=O)OC)=CC=C1N VWGIBJGZLCERFV-UHFFFAOYSA-N 0.000 description 1
- CEYHKCZODRRMMV-VIFPVBQESA-N methyl 4-amino-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 CEYHKCZODRRMMV-VIFPVBQESA-N 0.000 description 1
- HTYWVEUBCLGQES-VIFPVBQESA-N methyl 4-nitro-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 HTYWVEUBCLGQES-VIFPVBQESA-N 0.000 description 1
- RVRSGGHPMXSDSD-ZETCQYMHSA-N methyl 5-amino-6-[[(2S)-oxetan-2-yl]methylamino]pyridine-2-carboxylate Chemical compound NC=1C=CC(=NC=1NC[C@H]1OCC1)C(=O)OC RVRSGGHPMXSDSD-ZETCQYMHSA-N 0.000 description 1
- ILKIHCYHKYHCLM-ZETCQYMHSA-N methyl 5-nitro-6-[[(2S)-oxetan-2-yl]methylamino]pyridine-2-carboxylate Chemical compound [N+](=O)([O-])C=1C=CC(=NC=1NC[C@H]1OCC1)C(=O)OC ILKIHCYHKYHCLM-ZETCQYMHSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 150000006636 nicotinic acid Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
- CINJIXGRSTYIHP-UHFFFAOYSA-N oxolan-3-ylmethanamine Chemical compound NCC1CCOC1 CINJIXGRSTYIHP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 1
- 229950006544 saroglitazar Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229950001912 setmelanotide Drugs 0.000 description 1
- 108700030852 setmelanotide Proteins 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- KKTKXAAJDVFSAP-UHFFFAOYSA-N tert-butyl 2-[[4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[(3-ethylimidazol-4-yl)methyl]benzimidazole-5-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC2=CN=CN2CC)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F KKTKXAAJDVFSAP-UHFFFAOYSA-N 0.000 description 1
- FUBYQYGUUSRJIG-UHFFFAOYSA-N tert-butyl 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-(1,3-oxazol-2-ylmethyl)benzimidazole-5-carboxylate Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2CC=2OC=CN=2)C=C(C=C3)C(=O)OC(C)(C)C)C=C1)F FUBYQYGUUSRJIG-UHFFFAOYSA-N 0.000 description 1
- WCGKHZHOGLVVPU-UHFFFAOYSA-N tert-butyl 3-(trifluoromethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(C(F)(F)F)C1 WCGKHZHOGLVVPU-UHFFFAOYSA-N 0.000 description 1
- INRDKANIUHCVAP-UHFFFAOYSA-N tert-butyl 3-[(3-ethylimidazol-4-yl)methylamino]-4-nitrobenzoate Chemical compound C(C)N1C=NC=C1CNC=1C=C(C(=O)OC(C)(C)C)C=CC=1[N+](=O)[O-] INRDKANIUHCVAP-UHFFFAOYSA-N 0.000 description 1
- CXQXHHIIMBWMCH-UHFFFAOYSA-N tert-butyl 3-fluoro-4-nitrobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 CXQXHHIIMBWMCH-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- POYYHAMDUVMQJH-UHFFFAOYSA-N tert-butyl 4-(5-fluoro-6-oxo-1H-pyridin-2-yl)piperidine-1-carboxylate Chemical compound FC1=CC=C(NC1=O)C1CCN(CC1)C(=O)OC(C)(C)C POYYHAMDUVMQJH-UHFFFAOYSA-N 0.000 description 1
- AXSJUHYVBIMIBU-UHFFFAOYSA-N tert-butyl 4-(6-chloropyridin-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=CC1)c1cccc(Cl)n1 AXSJUHYVBIMIBU-UHFFFAOYSA-N 0.000 description 1
- IYOSJVKZFUGRSS-UHFFFAOYSA-N tert-butyl 4-[6-[(4-chloro-2-fluorophenyl)methoxy]pyridin-2-yl]piperidine-1-carboxylate Chemical compound ClC1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)C(=O)OC(C)(C)C)C=C1)F IYOSJVKZFUGRSS-UHFFFAOYSA-N 0.000 description 1
- KZSAHPSOMKFNPN-UHFFFAOYSA-N tert-butyl 4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidine-1-carboxylate Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)C(=O)OC(C)(C)C)C=C1)F KZSAHPSOMKFNPN-UHFFFAOYSA-N 0.000 description 1
- IZEUZQGSNCGIJD-UHFFFAOYSA-N tert-butyl 4-[6-[(4-cyanophenyl)methoxy]-5-fluoropyridin-2-yl]piperidine-1-carboxylate Chemical compound C(#N)C1=CC=C(COC2=C(C=CC(=N2)C2CCN(CC2)C(=O)OC(C)(C)C)F)C=C1 IZEUZQGSNCGIJD-UHFFFAOYSA-N 0.000 description 1
- YROZAFOQRDAYMG-UHFFFAOYSA-N tert-butyl 4-amino-3-[(3-ethylimidazol-4-yl)methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC(C)(C)C)C=C1)NCC1=CN=CN1CC YROZAFOQRDAYMG-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229950004996 tipelukast Drugs 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 1
- 229950010728 trelagliptin Drugs 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435533P | 2016-12-16 | 2016-12-16 | |
US62/435,533 | 2016-12-16 | ||
KR1020197020714A KR102314286B1 (ko) | 2016-12-16 | 2017-12-01 | Glp-1 수용체 작용제 및 이의 용도 |
PCT/IB2017/057577 WO2018109607A1 (en) | 2016-12-16 | 2017-12-01 | Glp-1 receptor agonists and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197020714A Division KR102314286B1 (ko) | 2016-12-16 | 2017-12-01 | Glp-1 수용체 작용제 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210127782A KR20210127782A (ko) | 2021-10-22 |
KR102466418B1 true KR102466418B1 (ko) | 2022-11-14 |
Family
ID=60702906
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217032471A KR102466418B1 (ko) | 2016-12-16 | 2017-12-01 | Glp-1 수용체 작용제 및 이의 용도 |
KR1020197020714A KR102314286B1 (ko) | 2016-12-16 | 2017-12-01 | Glp-1 수용체 작용제 및 이의 용도 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197020714A KR102314286B1 (ko) | 2016-12-16 | 2017-12-01 | Glp-1 수용체 작용제 및 이의 용도 |
Country Status (41)
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109843888B (zh) | 2016-10-24 | 2022-03-01 | 阿斯利康(瑞典)有限公司 | 可用于治疗癌症的6,7,8,9-四氢-3H-吡唑并[4,3-f]异喹啉衍生物 |
EP3555064B9 (en) * | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
EP4086256A1 (en) | 2016-12-16 | 2022-11-09 | Janssen Pharmaceutica NV | Small molecule inhibitors of the jak family of kinases |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
PE20191500A1 (es) | 2017-01-30 | 2019-10-22 | Astrazeneca Ab | Moduladores del receptor de estrogeno |
US20230194536A1 (en) * | 2017-11-15 | 2023-06-22 | Beth Israel Deaconess Medical Center, Inc. | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advance liver fibrosis |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
KR20210032936A (ko) | 2018-06-15 | 2021-03-25 | 리아타 파마슈티컬즈, 아이엔씨. | Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물 |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
US11858916B2 (en) * | 2018-06-15 | 2024-01-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
AU2019329884B2 (en) | 2018-08-31 | 2022-01-27 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
EP3883928A4 (en) * | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CN113853371B (zh) * | 2019-04-12 | 2024-05-03 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂及其用途 |
CN114041056A (zh) | 2019-04-29 | 2022-02-11 | 康福治疗有限公司 | 用于跨膜蛋白尤其是gpcr的筛选方法和测定 |
US20220387402A1 (en) * | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
JP7498199B2 (ja) | 2019-06-28 | 2024-06-11 | ファイザー・インク | 種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体 |
WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
CA3150108A1 (en) | 2019-09-13 | 2021-03-18 | Neelu Kaila | HPK1 ANTAGONISTS AND THEIR USES |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
US20230002348A1 (en) | 2019-11-15 | 2023-01-05 | Ildong Pharmaceutical Co., Ltd. | GLP-1 Receptor Agonist and Use Thereof |
KR20210059584A (ko) * | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
EP4069686A4 (en) * | 2019-12-02 | 2022-11-09 | Hyundai Pharm Co., Ltd. | GLP-1 RECEPTOR AGONIST |
CN115175893A (zh) * | 2019-12-10 | 2022-10-11 | 辉瑞公司 | 2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并[d][1,3]二氧杂环戊烯-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-苯并[d]咪唑-6-甲酸, 1,3-二羟基-2-(羟基甲基)丙烷-2-胺盐的固体形式 |
RS65238B1 (sr) * | 2019-12-10 | 2024-03-29 | Lilly Co Eli | Proces i međuproizvod za izradu oksetan-2-ilmetanamina |
WO2021155841A1 (en) | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
EP4103563A4 (en) * | 2020-02-13 | 2024-03-06 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
PE20230175A1 (es) * | 2020-03-18 | 2023-02-01 | Lg Chemical Ltd | Agonista del receptor de glp-1, composicion farmaceutica que comprende el mismo, y metodo para preparar el mismo |
IL296694A (en) * | 2020-03-27 | 2022-11-01 | Pfizer | Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts |
CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
JP2023524493A (ja) * | 2020-04-29 | 2023-06-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
TW202210473A (zh) | 2020-05-27 | 2022-03-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Glp-1r促效劑之鹽和晶型及其用途 |
EP4155313A4 (en) * | 2020-06-04 | 2023-09-13 | Hangzhou Sciwind Biosciences Co., Ltd. | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF |
EP4161927A1 (en) | 2020-06-09 | 2023-04-12 | Pfizer Inc. | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof |
WO2021249492A1 (zh) * | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
CN117645601A (zh) * | 2020-06-10 | 2024-03-05 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
WO2021254470A1 (zh) * | 2020-06-19 | 2021-12-23 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
CN113831337B (zh) * | 2020-06-24 | 2023-03-24 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
EP4192831A4 (en) * | 2020-08-06 | 2024-05-15 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
WO2022031994A1 (en) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
EP4199919A1 (en) * | 2020-08-21 | 2023-06-28 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
JP2023538949A (ja) * | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
WO2022068772A1 (zh) * | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
EP4227299A1 (en) * | 2020-10-12 | 2023-08-16 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Benzimidazolone glp-1 receptor agonist and use thereof |
US20240083886A1 (en) * | 2020-10-13 | 2024-03-14 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
AU2021359493A1 (en) * | 2020-10-14 | 2023-06-15 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
CN114478497B (zh) * | 2020-11-12 | 2023-10-20 | 杭州中美华东制药有限公司 | 芳基烷基酸类glp-1受体激动剂及其用途 |
US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
US20220213072A1 (en) * | 2020-12-15 | 2022-07-07 | Pfizer Inc. | Metabolites of glp1r agonists |
EP4269399A4 (en) * | 2020-12-25 | 2024-06-05 | Xizang Haisco Pharmaceutical Co., Ltd. | FIVE-MEMBERED RING DERIVATIVE AND MEDICINAL USE THEREOF |
MX2023008854A (es) * | 2021-01-28 | 2023-10-17 | Carmot Therapeutics Inc | Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso. |
WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
US20220306614A1 (en) * | 2021-03-11 | 2022-09-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022199458A1 (zh) | 2021-03-22 | 2022-09-29 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
EP4317145A1 (en) | 2021-03-24 | 2024-02-07 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
KR20230173708A (ko) | 2021-04-21 | 2023-12-27 | 길리애드 사이언시즈, 인코포레이티드 | 카르복시-벤즈이미다졸 glp-1r 조절 화합물 |
EP4334304A1 (en) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
CA3218345A1 (en) | 2021-05-20 | 2022-11-24 | Francisco Javier Agejas Chicharro | Macrocyclic glucagon-like peptide 1 receptor agonists |
CA3219984A1 (en) | 2021-06-24 | 2022-12-29 | Wenqiang ZHAI | Glp-1 receptor agonist and composition and use thereof |
WO2023001237A1 (en) * | 2021-07-21 | 2023-01-26 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
WO2023011395A1 (zh) * | 2021-08-02 | 2023-02-09 | 深圳信立泰药业股份有限公司 | Glp-1r激动剂化合物的盐及其制备方法和医药用途 |
CA3227366A1 (en) * | 2021-08-04 | 2023-02-09 | Yidong Su | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
BR112024002129A2 (pt) * | 2021-08-31 | 2024-04-30 | Pfizer | Formas sólidas de ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico, sal de 1,3-di-hidróxi-2-(hidroximetil)propan-2-amina |
CN113548982B (zh) * | 2021-09-03 | 2022-05-06 | 上海三牧化工技术有限公司 | 一种4-氰基-2-氟苄醇的制备方法 |
AU2022344074A1 (en) | 2021-09-08 | 2024-02-29 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
AU2022349020A1 (en) * | 2021-09-27 | 2024-05-09 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023066356A1 (zh) * | 2021-10-22 | 2023-04-27 | 盛世泰科生物医药技术(苏州)有限公司 | 作为glp-1受体激动剂的化合物及其用途 |
WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023098852A1 (en) * | 2021-12-03 | 2023-06-08 | Hangzhou Sciwind Biosciences Co., Ltd. | Crystal forms of thienoimidazole compound and preparation method thereof |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Glp-1受容体アゴニスト活性を有する芳香族複素環誘導体 |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023124824A1 (zh) * | 2021-12-29 | 2023-07-06 | 海思科医药集团股份有限公司 | 一种glp-1激动剂的盐及其晶型和在医药上的应用 |
WO2023130878A1 (zh) * | 2022-01-10 | 2023-07-13 | 海思科医药集团股份有限公司 | 一种glp-1激动剂盐及其晶型及在医药上的应用 |
WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
WO2023164050A1 (en) * | 2022-02-23 | 2023-08-31 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
WO2023169436A1 (zh) * | 2022-03-08 | 2023-09-14 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
WO2023169456A1 (en) * | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2024018395A1 (en) * | 2022-07-22 | 2024-01-25 | Pfizer Inc. | Methods and intermediates for preparing 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
CN115536638B (zh) * | 2022-08-15 | 2023-10-13 | 上海交通大学 | 一种三氮唑类化合物及其应用 |
WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
CN118184638A (zh) * | 2022-12-13 | 2024-06-14 | 杭州中美华东制药有限公司 | 盐型的glp-1受体激动剂、其晶型和制备方法及其药物组合物和用途 |
WO2024127297A1 (en) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
WO2024149080A1 (zh) * | 2023-01-13 | 2024-07-18 | 中国科学院上海药物研究所 | 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物 |
CN116675680B (zh) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | 一种氘代化合物及其制备方法、药物和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
WO1994021615A1 (en) | 1993-03-18 | 1994-09-29 | Merck Sharp & Dohme Limited | Benzimidazole derivatives |
US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
SE0100903D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US20040127504A1 (en) * | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
ES2882797T3 (es) | 2009-04-02 | 2021-12-02 | Merck Serono Sa | Inhibidores de dihidroorotato deshidrogenasa |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
-
2017
- 2017-12-01 EP EP17817174.0A patent/EP3555064B9/en active Active
- 2017-12-01 MY MYPI2019003381A patent/MY195385A/en unknown
- 2017-12-01 MD MDE20191184T patent/MD3555064T2/ro unknown
- 2017-12-01 MX MX2019007077A patent/MX2019007077A/es unknown
- 2017-12-01 EA EA201991193A patent/EA037318B1/ru unknown
- 2017-12-01 CU CU2019000056A patent/CU24573B1/es unknown
- 2017-12-01 HR HRP20221437TT patent/HRP20221437T1/hr unknown
- 2017-12-01 RU RU2019118485A patent/RU2740135C1/ru active
- 2017-12-01 SI SI201731287T patent/SI3555064T1/sl unknown
- 2017-12-01 JP JP2019531391A patent/JP6637641B1/ja active Active
- 2017-12-01 UA UAA201906738A patent/UA122035C2/uk unknown
- 2017-12-01 KR KR1020217032471A patent/KR102466418B1/ko active IP Right Grant
- 2017-12-01 LT LTEPPCT/IB2017/057577T patent/LT3555064T/lt unknown
- 2017-12-01 BR BR112019012211-7A patent/BR112019012211A2/pt active Search and Examination
- 2017-12-01 PL PL17817174.0T patent/PL3555064T3/pl unknown
- 2017-12-01 PT PT178171740T patent/PT3555064T/pt unknown
- 2017-12-01 WO PCT/IB2017/057577 patent/WO2018109607A1/en active Application Filing
- 2017-12-01 PE PE2019001229A patent/PE20191501A1/es unknown
- 2017-12-01 KR KR1020197020714A patent/KR102314286B1/ko active IP Right Grant
- 2017-12-01 AU AU2017374860A patent/AU2017374860B2/en active Active
- 2017-12-01 ES ES17817174T patent/ES2934789T3/es active Active
- 2017-12-01 GE GEAP201715110A patent/GEP20217265B/en unknown
- 2017-12-01 MA MA56480A patent/MA56480B1/fr unknown
- 2017-12-01 DK DK17817174.0T patent/DK3555064T5/da active
- 2017-12-01 RS RS20221178A patent/RS63849B9/sr unknown
- 2017-12-01 HU HUE17817174A patent/HUE060533T2/hu unknown
- 2017-12-01 FI FIEP17817174.0T patent/FI3555064T3/fi active
- 2017-12-01 CR CR20190289A patent/CR20190289A/es unknown
- 2017-12-01 CN CN201780086550.1A patent/CN110325530B/zh active Active
- 2017-12-13 US US15/839,901 patent/US10208019B2/en active Active
- 2017-12-13 TW TW106143701A patent/TWI713809B/zh active
- 2017-12-13 CA CA2988721A patent/CA2988721C/en active Active
- 2017-12-14 UY UY0001037514A patent/UY37514A/es not_active Application Discontinuation
- 2017-12-15 AR ARP170103545A patent/AR110387A1/es unknown
-
2018
- 2018-12-14 US US16/220,184 patent/US10669259B2/en active Active
-
2019
- 2019-06-07 EC ECSENADI201941071A patent/ECSP19041071A/es unknown
- 2019-06-11 CO CONC2019/0006046A patent/CO2019006046A2/es unknown
- 2019-06-12 IL IL267288A patent/IL267288B/en active IP Right Grant
- 2019-06-14 DO DO2019000166A patent/DOP2019000166A/es unknown
- 2019-06-14 CL CL2019001651A patent/CL2019001651A1/es unknown
- 2019-06-14 PH PH12019501360A patent/PH12019501360A1/en unknown
- 2019-07-15 ZA ZA2019/04616A patent/ZA201904616B/en unknown
- 2019-12-20 JP JP2019230341A patent/JP6982054B2/ja active Active
-
2020
- 2020-04-29 US US16/861,646 patent/US10851081B2/en active Active
- 2020-10-30 US US17/085,534 patent/US11512070B2/en active Active
-
2022
- 2022-10-24 US US18/049,052 patent/US11802121B2/en active Active
- 2022-12-22 CY CY20221100805T patent/CY1125716T1/el unknown
-
2023
- 2023-09-28 US US18/477,050 patent/US20240034725A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102466418B1 (ko) | Glp-1 수용체 작용제 및 이의 용도 | |
KR102542199B1 (ko) | Glp-1 수용체 작용제 및 이의 용도 | |
KR102538572B1 (ko) | Glp-1 수용체 효능제 및 그의 용도 | |
OA19245A (en) | GLP-1 receptor agonists and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |